Clinical Trial Update: H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial for Langerhans Cell Histiocytosis (H-9926-LCH III) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Snippet

Sponsor: University of New Mexico | Conditions: Leukemia | Phase 3 | Status: WITHDRAWN